Foghorn Therapeutics Inc.
NASDAQ:FHTXBiotechnology
+$0.10 today
- Market cap
- $107.33M
- Beta
- 2.89
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$1.08
Volume 0.53M
Average 0.15M
FHTX Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Foghorn Therapeutics Inc.NASDAQ: FHTX
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital declines year over year
Q1 FY2026 other working capital of $7.2M (cash outflow) fell 24.8% year over year, behind the -1.6% change in trailing-twelve-month other working capital. Sequentially, it fell 22.2% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.
Context
- Other working capital amounted to 105.5% of revenue in FY2025, down 26.3 pp from a year earlier.
- Other working capital grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -24.8% toward the trailing-twelve-month pace of -1.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (32.62M) USD
- Year-over-year change
- -9.5%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32.62M) | -9.5% |
| FY2024 | 2024-12-31 | (29.79M) | +30.3% |
| FY2023 | 2023-12-31 | (42.73M) | -112.9% |
| FY2022 | 2022-12-31 | (20.07M) | -106.0% |
| FY2021 | 2021-12-31 | 336.48M | — |
Other Working Capital vs competitors
How FHTX compares with its peers on the latest reported figures
- FHTX's LTM Mar 2026 other working capital of $30.25M is the 2nd largest of the 11 companies compared; the peer median is $1.48M.
- Its year-over-year change of -1.6% is the 5th highest of 11, against a peer median of -38.5%.
- Other working capital amounts to 107.2% of revenue for FHTX, versus a peer median of 43.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $36.58M | +102.5% | +204.1% | 51.5% | |
| LTM Mar 2026 | $30.25M | -1.6% | +17.6% | 107.2% | |
| LTM Mar 2026 | $19.64M | -71.6% | +51.1% | 43.3% | |
| LTM Mar 2026 | $12.07M | +107.2% | -30.5% | 210.3% | |
| LTM Mar 2026 | $4.33M | +147.2% | — | 2.0% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $3.42M | -171.5% | — | — |
| LTM Mar 2026 | $3.38M | -289.7% | — | 167.9% | |
| LTM Mar 2026 | $3.01M | +193.9% | — | 21.7% | |
| LTM Mar 2026 | $1.86M | -204.6% | — | — | |
| LTM Mar 2026 | $1.56M | -89.6% | — | 2.2% | |
ZURAZura Bio Limited | LTM Mar 2026 | $1.1M | -5.4% | — | — |
| Peer median (excluding FHTX) | $1.48M | -38.5% | +51.1% | 43.3% | |
Competitors are the stored peer set for FHTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (101.32M) | (108.88M) | (98.43M) | (86.62M) | (74.28M) |
| Depreciation & Amortization | 3.23M | 7.9M | 3.45M | 3.12M | 3.33M |
| Deferred Income Tax | 1.41M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.38M | 0 | 16.19M | 11.89M | 10.4M |
| Change in Working Capital | 33.44M | 281.55M | (41.88M) | (32.27M) | (32.14M) |
| Accounts Receivables | (300M) | 300M | 0 | 0 | 0 |
| Inventory | (3.17M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 135K | 1.61M | 846K | (2.48M) | 481K |
| Other Working Capital | 336.48M | (20.07M) | (42.73M) | (29.79M) | (32.62M) |
| Other Non-Cash Items | 4.61M | 13.05M | 2.56M | 3.47M | 6.59M |
| Operating Cash Flow | (50.25M) | 193.61M | (118.11M) | (100.41M) | (86.1M) |
| Capital Expenditures | (3.31M) | (1.21M) | (1.22M) | (906K) | (50K) |
| Acquisitions (Net) | (39.49M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (99.98M) | (409.35M) | (73.9M) | (261.47M) | (131.25M) |
| Sales of Investments | 139.47M | 166.23M | 219.58M | 232.47M | 243.34M |
| Other Investing Activities | 39.49M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 36.17M | (244.32M) | 144.45M | (29.9M) | 112.04M |
| Debt Repayment | (21.21M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 42.21M | 1.76M | 0 | 103.4M | 1.02M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.42M | 0 | 1.78M | 2.03M | 0 |
| Financing Cash Flow | 22.42M | 1.76M | 1.78M | 105.43M | 1.02M |
| Effect of Forex Changes | 0 | 25K | 0 | 0 | 0 |
| Net Change in Cash | 8.34M | (48.92M) | 28.12M | (24.88M) | 26.96M |
| Free Cash Flow | (53.56M) | 192.4M | (119.33M) | (101.31M) | (86.15M) |
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Intrinsic Alpha fair value
Locked
Current Price
$1.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.